Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. provides earnings guidance for the six months ended 30 June 2023. It is expected to record an unaudited net profit attributable to shareholders of the Company of approximately RMB 60 million to RMB 70 million during the Reporting Period, turning from losses into profits as compared with last year (six months ended 30 June 2022: unaudited net loss attributable to shareholders of the Company of approximately RMB 36 million). The unaudited net profit attributable to shareholders of the Company after deducting the non-recurring profit or loss is expected to be approximately RMB 50 million to RMB 60 million (six months ended 30 June 2022: unaudited net loss attributable to shareholders of the Company after deducting the non- recurring profit or loss of approximately RMB 46 million).